News

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.

Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials

Andrew G. Lee, MD, and Drew Carey, MD, discuss how baseline optical coherence tomography parameters can help ophthalmologists counsel patients and make more informed decisions after ethambutol-associated optic neuropathy.

The global prevalence of myopia has surged, and is expected to affect nearly 5 billion people by 2050

Baljean Dhillon, FRCPS, FRCS, FRCOphth, FRCPE, advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium.

Make the most of your practice and your retina conference participation.

Intracameral tPA can treat fibrinous clots in severe anterior uveitis.

Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and patient experience.

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Changing demographics and increasing trial complexity present challenges and opportunities.

The report divides the research into 7 categories: sex, gender, and hormones; epidemiology; pathophysiology; tear film; pain and sensation; iatrogenic; and clinical trial design.

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).

Patients in Ontario expose illegal user fees for cataract surgeries in private clinics, urging government action to uphold the Canada Health Act.

Catch up on this week's highlights in retina.

ZinserLab will focus on accelerating the development of imaging technologies in eye care.

A new study from China revealed a genetic link between coffee consumption and age-related macular degeneration (AMD).

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear Infirmary of Mount Sinai offers advanced options for every stage of life.

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

To conduct the study, the investigators obtained data on coffee consumption from genome‐wide association studies (GWAS) and the latest AMD‐related GWAS summary data from the Finngen consortium R11.

Funding will support continued product development, while the board is composed of “global leaders in posterior and anterior segment eye care, artificial intelligence and clinical trial design.”

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing reliance on low vision centers.

High-resolution optical coherence tomography illuminates crucial biomarkers in age-related macular degeneration, Dr Sadda said